Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Miromatrix Medical Inc. maintains 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 6 distinct art units, showing a diverse range of technical classifications for their biological and pharmaceutical filings. The portfolio is being reviewed by 6 distinct examiners, with each examiner handling exactly one action. This distribution indicates that no single examiner or art unit currently dominates the company's pending patent prosecution, requiring a broad strategy across multiple USPTO divisions.
GU, QINHUA is the busiest examiner with 1 pending action. This highlights the lack of concentration in the portfolio, as even the most active examiner for this company only manages a single case. For a practitioner, this means that the prosecution of these 6 pending office actions will likely proceed independently of one another. The involvement of 6 distinct art units further suggests that the company's innovations touch on several different specialized fields within biotechnology. This variety requires the legal team to be prepared for different examination styles and technical standards across the various art units. The current data reflects a decentralized prosecution environment where each application is subject to a unique set of examiner expectations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Multi-statute (no §101) | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GU, QINHUA | 1 | 76.2% | +27.1% |
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
| ESPERON, NATHAN GREGORY | 1 | 41.0% | +23.3% |
| EBBINGHAUS, BRIANA NOEL | 1 | 59.7% | +63.0% |
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18759375 | Manufacturing of Bioengineered Recellularized Organs and Methods of Use Thereof | GU, QINHUA | — |
| 18680248 | Methods and Uses of Differentiated Cells | KASAYAN, KATRIEL BARCELLANO | — |
| 18702789 | EXTRACORPOREAL ORGAN SUPPORT SYSTEM | ESPERON, NATHAN GREGORY | — |
| 17111577 | METHODS OF LIVER RECELLULARIZATION | BARRON, SEAN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17440914 | Improved Decellularization of Isolated Organs | EBBINGHAUS, BRIANA NOEL | 71d |
| 18759375 | Manufacturing of Bioengineered Recellularized Organs and Methods of Use Thereof | GU, QINHUA | — |
| 18702789 | EXTRACORPOREAL ORGAN SUPPORT SYSTEM | ESPERON, NATHAN GREGORY | — |
| 17111577 | METHODS OF LIVER RECELLULARIZATION | BARRON, SEAN C | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 1634 | 1 |
| 1799 | 1 |
| 1632 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18759375 | Manufacturing of Bioengineered Recellularized Organs and Methods of Use Thereof | GU, QINHUA | 1633 | §103§112 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18680248 | Methods and Uses of Differentiated Cells | KASAYAN, KATRIEL BARCELLANO | 1634 | §103§112 | Non-Final OA | — | Pending | May 31, 2024 |
| 18702789 | EXTRACORPOREAL ORGAN SUPPORT SYSTEM | ESPERON, NATHAN GREGORY | 1799 | §103§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 17440914 | Improved Decellularization of Isolated Organs | EBBINGHAUS, BRIANA NOEL | 1632 | §103 | Final Rejection | 71d | Pending | Sep 20, 2021 |
| 17111577 | METHODS OF LIVER RECELLULARIZATION | BARRON, SEAN C | 1653 | §102§103 | Final Rejection | — | Pending | Dec 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMiromatrix Medical Inc. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Qinhua Gu has the most, with 1 of Miromatrix Medical Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
